export const mockRevisions = [
  {
    id: 'rev-001',
    product_name: 'Neuroplexin',
    therapeutic_area: 'Neurology',
    stage: 'Market Launch',
    workflow_stage: 'revision_requested',
    priority_level: 'high',
    submitter_name: 'Dr. Michael Chen',
    submitter_email: 'michael.chen@neurotech.com',
    created_at: new Date(Date.now() - 7*24*60*60*1000).toISOString(),
    updated_at: new Date(Date.now() - 2*60*60*1000).toISOString(),
    indication: 'Migraine Prevention',
    target_audience: 'Neurologists, Patients',
    rejection_stage: 'seo_review',
    rejection_reason: 'Keywords need to focus more on "migraine prevention" rather than general pain management. Meta description exceeds character limit.',
    rejected_by: 'Sarah Johnson (SEO Team)',
    rejected_at: new Date(Date.now() - 1*24*60*60*1000).toISOString(),
    seo_reviewer: 'Sarah Johnson',
    ai_output: {
      seo_title: 'Neuroplexin - Advanced Migraine Prevention Treatment for Chronic Sufferers',
      meta_description: 'Discover Neuroplexin, a breakthrough CGRP antagonist offering superior migraine prevention with reduced side effects compared to traditional treatments. Clinical trials show 75% reduction in monthly migraine days.',
      h1_tag: 'Neuroplexin: Next-Generation Migraine Prevention',
      seo_keywords: ['chronic pain management', 'headache treatment', 'neurological medication']
    }
  },
  {
    id: 'rev-002',
    product_name: 'Cardiomax Plus',
    therapeutic_area: 'Cardiology',
    stage: 'Phase III',
    workflow_stage: 'revision_requested',
    priority_level: 'high',
    submitter_name: 'Emily Rodriguez',
    submitter_email: 'emily.r@cardiopharma.com',
    created_at: new Date(Date.now() - 10*24*60*60*1000).toISOString(),
    updated_at: new Date(Date.now() - 4*60*60*1000).toISOString(),
    indication: 'Atrial Fibrillation',
    target_audience: 'Cardiologists, Electrophysiologists',
    rejection_stage: 'mlr_review',
    rejection_reason: 'Clinical trial data references need peer-reviewed journal citations. Adverse event profile incomplete - missing bleeding risk information.',
    rejected_by: 'Dr. James Wilson (MLR Committee)',
    rejected_at: new Date(Date.now() - 3*24*60*60*1000).toISOString(),
    mlr_reviewer: 'Dr. James Wilson',
    ai_output: {
      seo_title: 'Cardiomax Plus - Novel Anticoagulant for AFib',
      meta_description: 'Cardiomax Plus offers superior stroke prevention in atrial fibrillation patients.',
      h1_tag: 'Cardiomax Plus: Advanced AFib Management',
      clinical_claims: ['90% stroke reduction', 'Lower bleeding risk than warfarin']
    }
  },
  {
    id: 'rev-003',
    product_name: 'InsuNext',
    therapeutic_area: 'Endocrinology',
    stage: 'Market Launch',
    workflow_stage: 'revision_requested',
    priority_level: 'medium',
    submitter_name: 'David Park',
    submitter_email: 'david.park@diabetescare.com',
    created_at: new Date(Date.now() - 5*24*60*60*1000).toISOString(),
    updated_at: new Date(Date.now() - 8*60*60*1000).toISOString(),
    indication: 'Type 1 Diabetes',
    target_audience: 'Endocrinologists, Patients, Caregivers',
    rejection_stage: 'client_review',
    rejection_reason: 'Brand voice too clinical - needs more patient-friendly language. Missing competitive positioning against Lantus and Tresiba.',
    rejected_by: 'Marketing Director',
    rejected_at: new Date(Date.now() - 1*24*60*60*1000).toISOString(),
    client_reviewer: 'Jennifer Liu',
    ai_output: {
      seo_title: 'InsuNext - Ultra-Long Acting Insulin for T1D',
      meta_description: 'InsuNext provides 48-hour insulin coverage with fewer injections.',
      brand_messaging: 'Freedom from frequent dosing'
    }
  },
  {
    id: 'rev-004',
    product_name: 'OncoBrite',
    therapeutic_area: 'Oncology',
    stage: 'Market Launch',
    workflow_stage: 'revision_requested',
    priority_level: 'high',
    submitter_name: 'Dr. Lisa Wang',
    submitter_email: 'lisa.wang@oncobrite.com',
    created_at: new Date(Date.now() - 14*24*60*60*1000).toISOString(),
    updated_at: new Date(Date.now() - 12*60*60*1000).toISOString(),
    indication: 'Metastatic Breast Cancer',
    target_audience: 'Oncologists, Patients',
    rejection_stage: 'mlr_review',
    rejection_reason: 'Survival data needs updated ASCO 2024 presentation references. Missing contraindications for pregnancy.',
    rejected_by: 'Dr. Robert Thompson (MLR)',
    rejected_at: new Date(Date.now() - 2*24*60*60*1000).toISOString(),
    mlr_reviewer: 'Dr. Robert Thompson',
    ai_output: {
      seo_title: 'OncoBrite - CDK4/6 Inhibitor for mBC',
      meta_description: 'OncoBrite extends progression-free survival in HR+/HER2- metastatic breast cancer.',
      clinical_data: 'PFS: 28.2 months vs 14.5 months (placebo)'
    }
  },
  {
    id: 'rev-005',
    product_name: 'RheumaShield',
    therapeutic_area: 'Immunology',
    stage: 'Pre-Launch',
    workflow_stage: 'revision_requested',
    priority_level: 'medium',
    submitter_name: 'Mark Stevens',
    submitter_email: 'mark.stevens@immunopharm.com',
    created_at: new Date(Date.now() - 3*24*60*60*1000).toISOString(),
    updated_at: new Date(Date.now() - 16*60*60*1000).toISOString(),
    indication: 'Psoriatic Arthritis',
    target_audience: 'Rheumatologists, Dermatologists',
    rejection_stage: 'seo_review',
    rejection_reason: 'H2 tags need restructuring for better user intent matching. Add more long-tail keywords for voice search optimization.',
    rejected_by: 'Tom Anderson (SEO Lead)',
    rejected_at: new Date(Date.now() - 1*24*60*60*1000).toISOString(),
    seo_reviewer: 'Tom Anderson',
    ai_output: {
      seo_title: 'RheumaShield - IL-23 Inhibitor for PsA',
      h2_tags: ['What is RheumaShield?', 'Clinical Efficacy', 'Safety Profile', 'Dosing Schedule'],
      long_tail_keywords: ['psoriatic arthritis treatment', 'IL-23 inhibitor side effects']
    }
  }
]